Abstract Japanese encephalitis (JE) is the most common viral encephalitis in Asia. IXIARO® is a Vero cell-derived, inactivated JE virus vaccine which has recently been approved in the US, Europe, Canada and Australia (trade name JESPECT). This overview of the safety and tolerability of IXIARO® , for 6 months after the first vaccination in 7 Phase III trials, includes: 3558 subjects with at least one IXIARO® vaccination, 435 subjects with a JE-VAX® (manufactured by BIKEN, distributed by Sanofi Pasteur) vaccination, and 657 with phosphate-buffered saline solution with 0.1% Al(OH)3 (PBS + Alum) control vaccination. The percentage of subjects reporting solicited local adverse events (AEs) with IXIARO® (54%) was similar to PBS + Alum vaccination (56%) as were solicited systemic adverse events (40% IXIARO® ; 40% PBS + Alum vaccination). JE-VAX® showed a higher frequency of subjects with solicited local adverse events (61%) but a slightly lower frequency of subjects with solicited systemic adverse events (36%). The frequency of subjects with any solicited and unsolicited AE with IXIARO® (64%) was also similar to PBS + Alum vaccination (61%) and JE-VAX® (64%); as for subjects with serious AEs (1% IXIARO® ; 2% PBS + Alum vaccination, 1% JE-VAX® ). No serious allergic reactions were observed in any group. This safety analysis indicates that IXIARO® has a favorable safety profile, comparable to PBS + Alum control vaccination and appears to have a better local tolerability profile than JE-VAX®.